Matloff 1982.

Methods	Randomised clinical trial.
Participants	Country: USA. Number randomised: 52. Post‐randomisation dropouts: 0 (0%). Revised sample size: 52. Mean age: 52 years. Females: 48 (92.3%). Symptomatic participants: not stated. AMA positive: 42 (80.8%). Responders: not stated. Mean follow‐up period (for all groups): minimum 24 months. Inclusion criteria Symptom status: not stated. AMA status: AMA‐positive and AMA‐negative participants. Response status: not stated.
Interventions	Participants were randomly assigned to 2 groups. Group 1: D‐penicillamine (n = 26). Further details: D‐penicillamine: 1 g/day; duration: not stated. Group 2: placebo (n = 26).
Outcomes	Mortality, adverse events.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: information not available.
Allocation concealment (selection bias)	Unclear risk	Comment: information not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: although placebo was used in this double‐blind trial, there was no mention about identical placebo.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: although placebo was used in this double‐blind trial, there was no mention about identical placebo.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: no post‐randomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: mortality and morbidity reported.
For‐profit bias	High risk	Quote: "We are indebted to Merck, Sharp and Dohme Research Laboratories for providing the D‐penicillamine and placebo tablets".
Other bias	Low risk	Comment: no other bias.